Efficacy and safety of Mudan granules for treatment of diabetic peripheral neuropathy: a multicenter, double-blind, placebo-controlled, randomized, clinical trial.

J EthnopharmacolApr 30, 2026 (epub)
Clinical ResearchNeurologyEndocrinology

De Jin, Qing Gao, Yuehong Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter, double-blind, placebo-controlled randomized trial evaluated the efficacy and safety of Mudan granules in 400 patients with diabetic peripheral neuropathy (DPN). After 24 weeks, the Mudan group showed a significant improvement in the Michigan Diabetic Neuropathy Score (MDNS) with a mean change of -4.80 compared to -2.66 in the control group.

Key findings

  • The mean change in MDNS was -4.80 for the Mudan group versus -2.66 for the control group.
  • The least squares mean MDNS change was -4.74 for Mudan and -2.72 for placebo.
  • A statistically significant difference in MDNS improvement was observed between the two groups.

Why it matters

The study provides evidence that Mudan granules may effectively alleviate symptoms of diabetic peripheral neuropathy, a common complication of diabetes that significantly impacts quality of life. Understanding new treatment options is essential for managing this condition.

Source

PubMed · PMID 42069162

Published in J Ethnopharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.